 |
12 Diseases |  |
1 Trial |
|
1 Trial |  |
156 News |  |
| «123 |
- |||||| Marizev (omarigliptin) / Merck (MSD)
Combination therapy: Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022) (clinicaltrials.gov) - Nov 19, 2012
P3, N=300, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting
- |||||||||| Marizev (omarigliptin) / Merck (MSD)
New P3 trial, Monotherapy: A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011) (clinicaltrials.gov) - Oct 28, 2012
P3, N=300, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||| Marizev (omarigliptin) / Merck (MSD)
Enrollment open: A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019) (clinicaltrials.gov) - Oct 21, 2012
P3, N=210, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Marizev (omarigliptin) / Merck (MSD)
Combination therapy: Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022) (clinicaltrials.gov) - Oct 9, 2012
P3, N=300, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||||||| Januvia (sitagliptin) / Merck (MSD), Marizev (omarigliptin) / Merck (MSD)
New P3 trial, Monotherapy: Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020) (clinicaltrials.gov) - Oct 8, 2012
P3, N=410, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||||||| Marizev (omarigliptin) / Merck (MSD)
New P3 trial: A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018) (clinicaltrials.gov) - Oct 8, 2012
P3, N=4000, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||||||| Marizev (omarigliptin) / Merck (MSD)
New P3 trial: A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019) (clinicaltrials.gov) - Oct 1, 2012
P3, N=210, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||||||| Marizev (omarigliptin) / Merck (MSD)
New P3 trial, Monotherapy: Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015) (clinicaltrials.gov) - Sep 30, 2012
P3, N=568, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||||||| Marizev (omarigliptin) / Merck (MSD)
Clinical: A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016) (clinicaltrials.gov) - Sep 9, 2012
P3, N=680, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Marizev (omarigliptin) / Merck (MSD)
Trial completion: A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009) (clinicaltrials.gov) - Apr 9, 2012
P1, N=49, Completed, Sponsor: Merck
Not yet recruiting --> Recruiting Active, not recruiting --> Completed